» Articles » PMID: 23558287

Malignant Otitis Externa: an Asian Perspective on Treatment Outcomes and Prognostic Factors

Overview
Publisher Wiley
Date 2013 Apr 6
PMID 23558287
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Malignant otitis externa (MOE) is a severe disease with varying outcomes. Despite advances in antibiotic treatment, a significant proportion still succumbs to this disease. We aimed to analyze the effect of clinical factors on prognosis and to review treatment outcomes in our institution.

Study Design: Case series with retrospective chart review of MOE cases from 2006 to 2011.

Setting: Department of Otolaryngology-Head and Neck Surgery, National University Hospital, Singapore, a tertiary referral center.

Subjects And Methods: Patients with MOE admitted for treatment were studied and divided into 2 outcome groups depending on response to a 6-week course of intravenous antibiotics. Demographic and disease factors were analyzed with regard to outcome.

Results: Nineteen cases were analyzed. Disease resolved in 63.2% after 6 weeks of antibiotics. Mortality was 21.1%. Age, diabetic control, duration of diagnostic delay, cranial nerve involvement, and inflammatory markers were not found to predict prognosis. Erythrocyte sedimentation rate and C-reactive protein levels correlated with disease activity and can be used to monitor progress. Clival involvement was associated with persistent disease (P = .002). Only 63.2% of cases had positive cultures. Pseudomonas aeruginosa was the main organism, and 33.3% of isolates were multidrug resistant. Outcome was not different in cases where culture-directed therapy was employed vs those where empirical ceftazidime and fluoroquinolone were used (P = .650).

Conclusion: Malignant otitis externa remains an insidious disease with significant mortality. Involvement of the clivus portends a poorer prognosis. Combination therapy with intravenous ceftazidime and oral fluoroquinolone remains relevant despite concerns of culture-negative cases and multidrug-resistant Pseudomonas.

Citing Articles

Malignant otitis externa: What is the role of surgery?.

Zhang L, Bonanno J, Byun W, Ren Y Laryngoscope Investig Otolaryngol. 2024; 9(6):e70029.

PMID: 39679169 PMC: 11645471. DOI: 10.1002/lio2.70029.


Microbial spectrum, management challenges, and outcome in patients with otogenic skull base osteomyelitis.

AlSharhan S, Alwazzeh M, ALRammah M, ALMarzouq W, AlGhuneem A, Alshrefy A Infez Med. 2024; 32(3):340-351.

PMID: 39282550 PMC: 11392546. DOI: 10.53854/liim-3203-8.


Diagnostic criteria and core outcome set development for necrotising otitis externa: the COSNOE Delphi consensus study.

Lodhi S, Dodgson K, Dykes M, Vishwanath V, Bazaz R, Mathur S J Laryngol Otol. 2024; 138(9):913-920.

PMID: 38644734 PMC: 11518678. DOI: 10.1017/S0022215124000513.


The Association Between Malignant Otitis Externa and Diabetes Mellitus in Africa: A Systematic Review.

Azeez T, Adeagbo A Indian J Otolaryngol Head Neck Surg. 2023; 75(4):3277-3287.

PMID: 37974885 PMC: 10645783. DOI: 10.1007/s12070-023-03939-3.


Clinico-Radiological Evaluation for Longitudinal Assessment in Central Skull Base Osteomyelitis: Proposal of Novel Scoring System.

Upreti G, Thomas R, Sundaresan R, Rebekah G, Rupali P, Jasper A Indian J Otolaryngol Head Neck Surg. 2023; 75(4):3553-3564.

PMID: 37974699 PMC: 10646027. DOI: 10.1007/s12070-023-03956-2.